ABOUT CINRYZE

Not real patients

Effectiveness of CINRYZE

Any time you're considering a new medication, the best thing you can do is talk with your doctor. It's also a good idea to learn about the safety and effectiveness of the medicine you're thinking about trying. The effect of CINRYZE has been studied in adults, teenagers and children (7-11 years old).


Pediatric Patients (aged 7-11 yrs old)
Number of HAE attacks per month during 12 week observation period and 12 week treatment period
Mean (average)
Baseline Observation
(12 Patients)
3.7
Cinryze®
500 U
(12 Patients)
1.2
Cinryze®
1,000 U
(12 Patients)
0.7

  • CINRYZE demonstrated a reduction in the number of HAE attacks (71.1% and 84.5% mean reduction with 500 U and 1,000 U, respectively) vs baseline attack rate
  • Both doses of CINRYZE also reduced the severity of attacks and use of acute treatment vs baseline

Pediatric Patient Study Design

The efficacy and safety of CINRYZE were evaluated in a 36-week clinical trial in 12 pediatric patients with HAE aged 7 to 11 years old. Patients were observed for 12 weeks to establish baseline attack rate, then given one dose of CINRYZE (500 U or 1,000 U every 3 or 4 days) for 12 weeks and then switched to the other dose for the last 12 weeks. Efficacy was measured as reduction in the number of attacks at 12 weeks for each treatment dose compared with the baseline observation attack rate.



Adult and Adolescent Patients
Number of HAE attacks during 12-week treatment
Mean (average)
Cinryze®
(22 Patients)
6.1
Placebo
(22 Patients)
12.7

  • The majority of patients had fewer attacks while on CINRYZE than while on placebo
  • The response to CINRYZE varied
    • 20 patients had fewer attacks, ranging from 100% to 1% fewer attacks
      — 4 patients had no attacks
    • 2 patients had more attacks, ranging from 8% to 85% more attacks

* P<0.0001 vs placebo

CINRYZE helped prevent attacks in most adolescent and adult patients

The main focus of this clinical trial was to see how many attacks patients experienced while taking CINRYZE compared to when they were taking placebo. While on CINRYZE, the majority of patients had fewer attacks. The response to CINRYZE, however, varied. Of the 22 adult and adolescent patients who participated in the clinical trial, 20 had fewer attacks, including 4 who had no attacks, while 2 had more attacks.

Adult and adolescent patients

In a clinical trial of 22 adult and adolescent patients with hereditary angioedema (HAE), CINRYZE reduced the frequency, duration and severity of attacks compared to placebo.

CINRYZE helped reduce the severity and duration of attacks

The length of attacks, days of swelling and severity of attacks were also measured. When adult and adolescent patients treated with CINRYZE experienced HAE attacks, they were shorter and less severe.


Average length of attack

Days
4
3
2
1
0
Placebo3.4
CINRYZE2.1

(p<0.01)

Adults and adolescents treated with
CINRYZE experienced

66%
reduction in
days of swelling

(p<0.0001)

The safety and effectiveness of CINRYZE were evaluated in a 24-week clinical trial of 22 adults and adolescents. Participants in the study were diagnosed with HAE and had a history of at least two attacks per month. Patients were divided into two groups: one group received CINRYZE for the first 12 weeks and switched to placebo for the last 12 weeks; the other group received placebo for the first 12 weeks and switched to CINRYZE for the last 12 weeks.

What could fewer HAE attacks mean for you?

Talk to your doctor to see if preventative therapy with CINRYZE might be right for you or a loved one.

Create your discussion guide

Definition: